The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database
Affiliations
- PMID: 32650374
- DOI: 10.3390/cancers12071829
Abstract
Background: To evaluate the performance of the 21-gene recurrence score (RS) assay in predicting chemotherapy benefit in the Surveillance, Epidemiology, and End Results population, we aimed to assess breast cancer-specific mortality (BCSM) by chemotherapy use within each of the RS categories.
Methods: Data on breast cancer (BC) cases diagnosed between 2004 and 2015 with available RS results were released. Our analysis included patients with hormone receptor-positive, node-negative early-stage BC (n = 89,402), and three RS groups were defined; RS < 11, low; RS 11-25, intermediate; RS > 25, high. A propensity score matched-analysis was performed to assess and compare BCSM.
Results: Chemotherapy was significantly associated with a reduced risk of BC death among patients in the high RS group (hazard ratio = 0.782; 95% CI, 0.618-0.990; p = 0.041). However, in the low and intermediate RS groups, there were no significant differences in BCSM between patients who received chemotherapy and those who did not. Among those with RS 11-25, chemotherapy benefit varied with tumor size (p = 0.001).
Conclusions: Our findings provide real-world evidence that the 21-gene RS assay is predictive of chemotherapy benefit among patients in clinical practice. More refined risk estimates would be needed for patients with an intermediate RS.
Keywords: breast cancer; chemotherapy; genomic assay; mortality; observational study.
Similar articles
- 21-gene recurrence score testing utilization among older women from different races: A population-based study.J Geriatr Oncol. 2020 Jul 7:S1879-4068(20)30058-8. doi: 10.1016/j.jgo.2020.06.004. Online ahead of print.PMID: 32646620
- Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.NPJ Breast Cancer. 2019 Nov 8;5:41. doi: 10.1038/s41523-019-0137-3. eCollection 2019.PMID: 31728408 Free PMC article.
- Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?Cancer. 2019 Jan 15;125(2):213-222. doi: 10.1002/cncr.31818. Epub 2018 Nov 2.PMID: 30387876 Free PMC article.
- Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.NPJ Breast Cancer. 2018 Aug 20;4:27. doi: 10.1038/s41523-018-0082-6. eCollection 2018.PMID: 30155517 Free PMC article. Review.
- Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.Breast. 2009 Oct;18 Suppl 3:S141-5. doi: 10.1016/S0960-9776(09)70290-5.PMID: 19914534 Review.
No hay comentarios:
Publicar un comentario